Cellebrite CLBT: Q2 Miss, CEO Exit, 32% Drop

Cellebrite's shares plunged 32% after the digital forensic software maker missed Q2 revenue targets, slashed full-year guidance, and installed a new CEO in a single day.

Lead

What Happened

Cellebrite posted Q2 2026 revenue of $131.1 million, representing 16% year-over-year growth but falling short of analyst expectations near $134.5 million. Annual recurring revenue for the quarter reached $508 million, below the company's internal guidance range, making the miss on the most critical SaaS metric particularly damaging.

Management identified three converging headwinds. First, several large transactions slipped the quarter — not lost, executives stressed, but delayed by new customer procurement processes, foreign-entity review requirements, and data-sovereignty concerns tied to cloud and artificial intelligence deployments. Second, migrations from the legacy Inseyets platform onto Cellebrite's newer architecture generated less pricing uplift and seat expansion than the company had modeled. Third, the added layer of AI-specific procurement scrutiny from government buyers created approval timelines longer than historical norms.

Net income declined sharply on a reported basis, even as adjusted EBITDA held closer to plan.

CEO Transition

The leadership change was the day's most consequential headline. Thomas E. Hogan, who had served as chief executive, was succeeded immediately by Shiv Ramji, who had joined Cellebrite only in May 2026 as President, Products and Technology. Ramji simultaneously joined the company's Board of Directors.

On the earnings call, Ramji offered a candid opening: "This was not the quarter we expected, and we have work to do." The direct ownership of the shortfall — delivered by the incoming CEO hours into his tenure — set a markedly different tone from a typical transition narrative, signaling that the board views the issues as execution-driven and addressable rather than structural.

Guidance Reset

Cellebrite cut its full-year 2026 ARR guidance to $550 million–$560 million, a reduction of roughly $15 million at the midpoint versus the prior range. Full-year revenue guidance was revised to $555 million–$561 million. Notably, the company raised its adjusted EBITDA guidance to $153 million–$159 million, suggesting management believes it can protect profitability even as topline momentum slows.

That EBITDA upgrade was insufficient to cushion investor reaction to the revenue and ARR revisions.

Market Reaction

CLBT shares fell more than 31% in pre-market trading immediately following the release and extended losses through the regular session, closing down approximately 29% near $10.38. Trading volume surged well above the 30-day average. Shareholder law firm Levi & Korsinsky disclosed an investigation into potential claims related to the guidance revision and share-price decline.

Bright Spots

Not all operating metrics disappointed. Revenue from Cellebrite's newer growth products — Guardian, Pathfinder, and Corellium — more than doubled year-over-year, demonstrating demand for the company's expanded platform beyond core mobile extraction. Cellebrite also began generating initial commercial revenue from its Genesis AI solution during the quarter, its first direct monetization of AI-assisted investigative capabilities.

Strategic Context

Cellebrite occupies a specialized niche within the forensic software market: its tools are used predominantly by government clients — domestic law enforcement, federal agencies, and allied-nation intelligence services — making its sales cycle unusually sensitive to procurement policy, budget authorization calendars, and geopolitical considerations around cloud and data sovereignty. The shift toward cloud delivery and AI-augmented analytics, while strategically necessary, has added procurement complexity that the company visibly underestimated heading into 2026.

Outlook

Ramji's immediate priority is accelerating stalled large-deal closures and improving the revenue conversion from Inseyets migrations. The raised EBITDA target indicates margin discipline remains intact, but investor confidence will require sequential improvement in ARR additions in the back half of 2026. The combination of a guidance reset, leadership change, and legal scrutiny leaves limited room for further execution missteps before the growth narrative faces more fundamental questions.